PHT Corporation SitePad® Used To Collect Electronic Data For Celgene Corporation's Recently Approved OTEZLA (apremilast) Tablets
Published: May 01, 2014
BOSTON & GENEVA--(BUSINESS WIRE)--Celgene Corporation used the PHT Corporation SitePad® System to collect primary and secondary endpoints for studies of its Otezla (apremilast) drug which the FDA approved in March 2014 to treat adults with active psoriatic arthritis (PsA).
PHT is the leading provider of technologies used to collect patient-driven eData for clinical research. The PHT SitePad System includes a large-screen mobile tablet for capturing study-specific clinician and patient assessments at the investigative site. Real-time access to all the data collected is available in StudyWorks™, the PHT online portal for data review and management. Using the SitePad System helps to increase the quality of the data collected, the time to database lock and reduces monitoring time and costs.
Help employers find you! Check out all the jobs and post your resume.